These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19779492)

  • 41. MCM8- and MCM9 Deficiencies Cause Lifelong Increased Hematopoietic DNA Damage Driving p53-Dependent Myeloid Tumors.
    Lutzmann M; Bernex F; da Costa de Jesus C; Hodroj D; Marty C; Plo I; Vainchenker W; Tosolini M; Forichon L; Bret C; Queille S; Marchive C; Hoffmann JS; Méchali M
    Cell Rep; 2019 Sep; 28(11):2851-2865.e4. PubMed ID: 31509747
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MiR-128-2 inhibits common lymphoid progenitors from developing into progenitor B cells.
    Yang Y; Xu J; Chen H; Fei X; Tang Y; Yan Y; Zhang H; Zhang J
    Oncotarget; 2016 Apr; 7(14):17520-31. PubMed ID: 27008703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SSB1/SSB2 Proteins Safeguard B Cell Development by Protecting the Genomes of B Cell Precursors.
    Pfeifer M; Brem R; Lippert TP; Boulianne B; Ho HN; Robinson ME; Stebbing J; Feldhahn N
    J Immunol; 2019 Jun; 202(12):3423-3433. PubMed ID: 31085591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Distinct oncogenic phenotypes in hematopoietic specific deletions of Trp53.
    Palanichamy JK; Tran TM; King JK; Katzman S; Ritter AJ; Sharma G; Tso C; Contreras JR; Fernando TR; Sanford JR; Rao DS
    Sci Rep; 2023 May; 13(1):7490. PubMed ID: 37160922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. p53 Signaling and cell cycle checkpoints.
    Stewart ZA; Pietenpol JA
    Chem Res Toxicol; 2001 Mar; 14(3):243-63. PubMed ID: 11258974
    [No Abstract]   [Full Text] [Related]  

  • 46. The DDB1-DCAF2 complex is essential for B cell development because it regulates cell cycle progression.
    Xue Z; Guo J; Ma R; Zhou L; Guo Y; Cang Y; Fan H; Chen J; Qian W; Wang L
    Cell Mol Immunol; 2021 Mar; 18(3):758-760. PubMed ID: 32139885
    [No Abstract]   [Full Text] [Related]  

  • 47. Mutant mice lacking alternatively spliced p53 isoforms unveil
    Fajac A; Simeonova I; Leemput J; Gabriel M; Morin A; Lejour V; Hamon A; Rakotopare J; Vaysse-Zinkhöfer W; Eldawra E; Pinskaya M; Morillon A; Bourdon JC; Bardot B; Toledo F
    Elife; 2024 Sep; 13():. PubMed ID: 39298333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The splicing regulators TIA1 and TIAL1 are required for the expression of the DNA damage repair machinery during B cell lymphopoiesis.
    Osma-Garcia IC; Capitan-Sobrino D; Mouysset M; Aubert Y; Maloudi O; Turner M; Diaz-Muñoz MD
    Cell Rep; 2022 Dec; 41(12):111869. PubMed ID: 36543128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers.
    Vázquez-Jiménez A; Avila-Ponce De León UE; Matadamas-Guzman M; Muciño-Olmos EA; Martínez-López YE; Escobedo-Tapia T; Resendis-Antonio O
    Front Immunol; 2021; 12():705646. PubMed ID: 34603282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Silencing of Testin expression is a frequent event in spontaneous lymphomas from Trp53-mutant mice.
    Weeks RJ; Ludgate JL; Le Mée G; Khanal R; Mehta S; Williams G; Slatter TL; Braithwaite AW; Morison IM
    Sci Rep; 2020 Oct; 10(1):16255. PubMed ID: 33004921
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of p53 inhibitors: progress, challenges and perspectives.
    Sanz G; Singh M; Peuget S; Selivanova G
    J Mol Cell Biol; 2019 Jul; 11(7):586-599. PubMed ID: 31310659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Converse Smith-Martin cell cycle kinetics by transformed B lymphocytes.
    Pham K; Kan A; Whitehead L; Hennessy RJ; Rogers K; Hodgkin PD
    Cell Cycle; 2018; 17(16):2041-2051. PubMed ID: 30205749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ∆133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling.
    Campbell H; Fleming N; Roth I; Mehta S; Wiles A; Williams G; Vennin C; Arsic N; Parkin A; Pajic M; Munro F; McNoe L; Black M; McCall J; Slatter TL; Timpson P; Reddel R; Roux P; Print C; Baird MA; Braithwaite AW
    Nat Commun; 2018 Jan; 9(1):254. PubMed ID: 29343721
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The proline rich domain of p53 is dispensable for MGMT-dependent DNA repair and cell survival following alkylation damage.
    Baran K; Yang M; Dillon CP; Samson LL; Green DR
    Cell Death Differ; 2017 Nov; 24(11):1925-1936. PubMed ID: 28753207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.
    Kazantseva M; Hung NA; Mehta S; Roth I; Eiholzer R; Rich AM; Seo B; Baird MA; Braithwaite AW; Slatter TL
    Sci Rep; 2017 May; 7(1):1566. PubMed ID: 28484276
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12.
    Slatter TL; Wilson M; Tang C; Campbell HG; Ward VK; Young VL; Van Ly D; Fleming NI; Braithwaite AW; Baird MA
    Oncoimmunology; 2016 Mar; 5(3):e1112941. PubMed ID: 27141366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development.
    Adams CJ; Yu JS; Mao JH; Jen KY; Costes SV; Wade M; Shoemake J; Aina OH; Del Rosario R; Menchavez PT; Cardiff RD; Wahl GM; Balmain A
    Mol Carcinog; 2016 Sep; 55(9):1387-96. PubMed ID: 26310697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Δ122p53, a mouse model of Δ133p53α, enhances the tumor-suppressor activities of an attenuated p53 mutant.
    Slatter TL; Hung N; Bowie S; Campbell H; Rubio C; Speidel D; Wilson M; Baird M; Royds JA; Braithwaite AW
    Cell Death Dis; 2015 Jun; 6(6):e1783. PubMed ID: 26068791
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phosphatase Wip1 controls antigen-independent B-cell development in a p53-dependent manner.
    Yi W; Hu X; Chen Z; Liu L; Tian Y; Chen H; Cong YS; Yang F; Zhang L; Rudolph KL; Zhang Z; Zhao Y; Ju Z
    Blood; 2015 Jul; 126(5):620-8. PubMed ID: 26012568
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.